If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cyramza Summary of Product Characteristics (SmPC)
Cyramza® (ramucirumab): Administration Using Filter
Administer ramucirumab via infusion pump. A separate infusion line must be used for the infusion and the line must be flushed with sterile sodium chloride (0.9%) solution for injection at the end of the infusion.
Using a Protein-Sparing Filter
filter is recommended to remove any possible particles (which include
micro-organisms) that may have been inadvertently introduced during
the preparation for infusion. Ramucirumab is compatible with a 0.2
micron protein sparing (low protein binding) filter and a 0.2
micron protein sparing (low protein binding) filter of at least 4.2
area may be used for administration.1
of the Same Filter
clinical studies, when ramucirumab was administered in combination
with another treatment, the filter was changed between the
administration of ramucirumab and the administration of other
refer to the local labeling for other products for details on
Using the Same Infusion Line
is acceptable to use a single/same IV line to administer ramucirumab
either before, or after, another medication if the infusion line used
is properly flushed with normal saline prior to administering the
ramucirumab through the same line.1
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review:April 17, 2020
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org